why choose us

First received: August 17, 2022

Clinical Trial: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Ulcerative Colitis

Study Type: INTERVENTIONAL


Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Act

Brief Summary: This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e.azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23),…

Read more